Medication info

Sitamero Tablet 50/500 mg

Prescription medicationApproval withdrawn
Ingredient · strength
Sitagliptin Phosphate Hydrate›Strength being verifiedMetformin Hydrochloride›Strength being verified
Manufacturer / importer
Dongkuk Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
PTP - 28 tablets/box[(14 tablets/PTP*2)], PTP - 56 tablets/box[(14 tablets/PTP*4)]
Approval status
Approval withdrawn

MFDS item code 201505844 · Approved 2015.08.20

This product's status changed to Approval withdrawn on 2023.08.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
In antidiabetic therapy, the dose of this medicine should be determined according to each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the starting dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended starting dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Dongkuk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used as an adjunct to diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be administered to patients who have never received diabetes medication treatment before or when adequate blood sugar control cannot be achieved with monotherapy. Additionally, it may be used when effects from monotherapy with metformin or sitagliptin are insufficient, or as a replacement for a combination therapy with these two medications. Even when combined with other medications, if blood sugar control is not sufficient, this medication can be added to enhance treatment efficacy. For example, it helps improve blood sugar control when used in combination with sulfonylureas, thiazolidinediones, and insulin. Overall, this medication is used to enhance blood sugar control in various treatment situations.

Dosage and Administration

Adult dosage

In antidiabetic therapy, the dose of this medicine should be determined according to each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medicine should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who have difficulty achieving adequate glycemic control with monotherapy, or who cannot achieve adequate glycemic control with sitagliptin monotherapy, the starting dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - The recommended starting dose of this medicine for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient’s current metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication is used for the treatment of diabetes and helps in controlling blood sugar levels. While taking this medication, there is a risk of severe allergic reactions; therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. There is a risk of pancreatitis, which is inflammation of the pancreas; therefore, immediate medical attention is required if symptoms such as sudden abdominal pain, vomiting, or fever occur. This medication should not be administered to patients with severely impaired renal function, severe infections, congestive heart failure, or acute myocardial infarction. If these conditions are suspected, it is essential to inform the physician. It is advisable for women who are pregnant or may become pregnant, as well as those who are breastfeeding, to avoid taking this medication. During treatment, it is important to be vigilant for symptoms of hypoglycemia, as the risk of hypoglycemia increases, especially when taken with insulin or other antidiabetic agents, necessitating immediate appropriate action if symptoms occur. This medication may affect liver and kidney function; therefore, regular blood tests to monitor liver and kidney status are necessary. Gastrointestinal adverse effects such as severe diarrhea, nausea, vomiting, and abdominal pain may occur; if symptoms are severe, consult a physician. Alcohol consumption may increase the risk of side effects of this medication; therefore, excessive drinking should be avoided during treatment. If surgery is imminent or the patient is in a poor condition due to severe infections or traumatic injuries, it is advisable to temporarily discontinue the medication and to resume it when the condition improves. There may be drug interactions with specific medications; thus, inform the physician or pharmacist about any other medications being taken. Elderly patients may have decreased renal function; therefore, dosage adjustments and regular kidney function tests are necessary. In case of overdose, immediate medical attention should be sought, as this medication can be partially removed through hemodialysis. During this medication, it is important to regularly monitor blood sugar, kidney function, liver function, and hematological values to check for any abnormalities.

Side effects

  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • peripheral edema
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • dermatitis
  • anorexia
  • weight loss
  • dyspnea
  • unstable angina
  • dizziness
  • acute renal failure
  • decreased appetite
  • gastrointestinal disturbance
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight, closed container at room temperature between 1°C to 30°C. Storing it this way will help maintain its efficacy and prevent deterioration.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

PTP - 28 tablets/box[(14 tablets/PTP*2)], PTP - 56 tablets/box[(14 tablets/PTP*4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.